人生物活性骨硬化蛋白檢測試劑盒（酶聯免疫法） 本產品僅供科研使用
bioactive SCLEROSTIN ELISA
| 貨號 | BI-20472 |
| 方法學: | Sandwich ELISA |
| 樣本類型: | 血清 ，血漿（EDTA, citrate), 細胞培養上清液 ，尿液 |
| 標準品範圍 | 0-320 pmol/l (7 serum based standards) |
| 標準品: | 0/10/20/40/80/160/320 pmol/l |
| 質控品: | 2個 |
| 樣本量: | 20 μl |
| 孵育時間: | 2 h / 1 h / 30 min |
| 單位換算: | 1 pg/ml = 0.044 pmol/l (MW: 22.5 kDa) |
靈敏度:
LOD: 1.9 pmol/l (0 pmol/l + 3 SD); LLOQ: 1.3 pmol/l
精密度
：
Intra-assay (n=3) ≤ 1%, Inter-assay (n=7) ≤ 5%
回收率:
The mean recovery of recombinant Sclerostin (spike: 26 pmol/l and 110 pmol/l) in human samples is:
serum (n=5): 93% / 86%
EDTA plasma (n=5): 94% / 93%
citrate plasma (n=1): 104% / 99%
稀釋線性:
Expected average dilution of recombinant Sclerostin in human samples for 1+1, 1+3 and 1+7 dilution is:
serum (n=6): 98% / 86% / 89%
EDTA plasma (n=6): 102% / 99% / 91%
citrate plasma (n=1): 119% / 132% / 103%
Expected average dilution of endogenous Sclerostin in human samples for 1+1, 1+3 and 1+7 dilution is:
serum (n=7): 100% / 103% / 106%
EDTA plasma (n=6): 105% / 108% / 123%
citrate plasma (n=2): 91% / 91% / 103%
交叉反應性:
The assay does not detect Noggin.
The assay does not detect Wise (SOSTDC1).
健康人群血清樣本參考值
：
Median (serum, n=32): 61.5. pmol/l
Median (EDTA plasma, n=24): 87 pmol/l
Median (citrate plasma, n=24): 61.5. pmol/l
推薦實驗室建立自己的參考值
。
Literature:
1.
Ott SM, et al.
J Clin Endocrinol Metab, 2005; 90(12):6392-6395
PMID: 16330810
2.
Semenov M et al.,
J Biol Chem, 2005; 280(29):26770-26775.
PMID: 15908424
3.
Veverka V et al.,
J Biol Chem, 2009; 284:10890-10900.
PMID: 19208630
4. Holdsworth G et al.,
J Biol Chem, 2012; 284(16), 287(32): 26464-26477.
5.
Hernandez P et al.,
Biochem Biophys Res Commun, 2014; 446 (4):1108-1113.
PMID: 24667598
6.
Durosier C et al.,
J Clin Endocrinol Metab, 2013; 98 (9):3873-3883.
PMID: 23864703
7.
van Lierop AH et al.,
J Clin Endocrinol Metab, 2012; 97:E1953-E1957.
PMID: 22844062
8.
Dallas SL et al.,
Endocrine Rev, 2013; 34:658-690.
PMID: 23612223
9.
van Bezooijen RL et al.,
J Dent Res, 2009; 88(6):569-574.
PMID: 19587164
10.
Wergedal, JE et al.,
J Clin Endocrinol Metab, 2003; 88:5778.
PMID: 14671168
11.
Costa AG et al.,
J Clin Endocrinol Metab, 2011; 96: 3804-3810.
PMID: 21937621
12.
Yavropoulou MP et al.,
Bone, 2012; 51:153-157.
PMID: 22579776
13.
Terpos E et al.,
Int J Cancer, 2012; 131:1466-1471.
PMID: 22052418
14.
Van Lierop AH et al.,
Eur J Endocrinol, 2010; 163:833-837.
PMID: 20817762
15.
Robling AG et al.,
J Musculoskelet Neuronal Interact, 2006; 6(4):354.
PMID: 18089564
16.
Garnero P et al.,
Osteoporos Int, 2013; 13; 24(2):489-494.
PMID: 22525978
17.
Amrein K et al.,
J Clin Endocrinol Metab, 2012; 97:148-154.
PMID: 21994959
18.
Cejka D et al.,
Clin J am Soc Nephrol, 2012; 6: 877-882.
PMID: 21164019
19.
Pelletier S et al.,
Clin J am Soc Nephrol, 2013; 8 (5): 819-823.
PMID: 23430206
20. Cejka D et al.,
J Clin Endocrinol Metab, 2014; 99(1):248-255.
PMID: 24187403
21.
Malluche HH et al.,
Clin J Am Soc Nephrol, 2014; 9:1254-1262.
PMID: 24948144
22.
Kanbay M et al.,
J. Clin. Endocrinol Metab, 2014; 99:E1854-E1861.
PMID: 25057883
23.
Viaene L et al.,
Nephrol Dial Transplant, 2013; 28:3024-3030.
PMID: 23605174
24.
McClung MR, et al.
Bone, 2017; 96:3-7.
PMID: 28115281
25. Costa AG et al.,
Bone, 2017; 96:24-28.
PMID: 27742501
26.
MT Drake and S Khosla
Bone, 2017; 96:8-17.
PMID: 27965160
ISN Frontiers Tokyo Feb 2018 - #P-300